NINGBO INNO PHARMCHEM CO.,LTD. is shedding light on 1-(2-Iodoethyl)-4-octylbenzene, a compound identified by CAS number 162358-07-8, which serves as a crucial link in pharmaceutical intermediate supply chains. This 'pharmaceutical intermediate' is characterized by its light yellow liquid appearance and is indispensable for the synthesis of essential drugs, particularly Fingolimod Hydrochloride, where it acts as a key precursor.

The intricate world of 'organic synthesis' relies on the precise availability and quality of chemical building blocks. 1-(2-Iodoethyl)-4-octylbenzene exemplifies this, playing a vital role as a 'fingolimod hydrochloride intermediate'. The demand to 'buy 1-(2-iodoethyl)-4-octylbenzene' underscores its significance in ensuring the smooth progression of drug development and manufacturing processes. NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to bolstering these supply chains.

For effective 'drug discovery' and the scaled-up production of pharmaceuticals, a robust 'chemical synthesis' framework is essential. This includes the reliable sourcing of intermediates that meet strict quality parameters. The identifier 'CAS 162358-07-8' ensures that companies procure the exact compound required for their specific 'pharmaceutical intermediate synthesis' needs, promoting consistency and safety.

NINGBO INNO PHARMCHEM CO.,LTD. understands that the performance of the final drug product is directly influenced by the quality of its intermediates. Therefore, we focus on providing materials that adhere to international standards. The compound, also known by its synonym 4-octylphenethyl iodide, is a key component that enables the creation of complex therapeutic molecules, supporting innovation and accessibility in healthcare.

In conclusion, 1-(2-Iodoethyl)-4-octylbenzene represents more than just a chemical; it is a vital connector in the pharmaceutical value chain. NINGBO INNO PHARMCHEM CO.,LTD. is committed to strengthening these connections by ensuring a consistent and high-quality supply of this critical intermediate, thereby supporting the pharmaceutical industry's mission to improve global health.